Institutional members access full text with Ovid®

Share this article on:

Co‐prescribing azathiopurine or 6‐mercaptopurine and 5‐aminosalicylate compounds in ulcerative colitis

Mayberry, H.1; Moshkovska, T. MD1; Mayberry, J. F. MD1*

doi: 10.1002/ibd.20750
Original Article

Background:: A total of 254 senior consultant gastroenterologists with valid e‐mail addresses were identified from the membership list of the British Society of Gastroenterology (BSG) 2007.

Methods:: They were sent by e‐mail a questionnaire which dealt with aspects of clinical practice and addressed cancer prevention in ulcerative colitis (UC). Replies were received from 97 clinicians (38% response rate).

Results:: Ninety‐one (94%) advised patients with established UC to take 5‐aminosalicylate (5‐ASA) compounds for life. Seventy‐two of the 91 (79%) clinicians co‐prescribed 5‐ASA compounds with immune modulators for patients with UC. Only 3 clinicians advised patients to take folic acid as a daily supplement. A median of 20% (interquartile range 10%–50%) of their patients with UC were co‐prescribed a 5‐ASA compound and azathioprine or 6‐mercaptopurine. Of these, a median of 3.5% (interquartile 1%–5%) developed neutropenia.

Conclustions:: Future research needs to be directed at the long‐term maintenance treatment and to address questions about which drugs should be used, in what combinations, and with what frequencies.

1 Department of Digestive Diseases, Leicester General Hospital, Leicester, United Kingdom

* Department of Digestive Diseases, Leicester General Hospital, Gwendolen Road, Leicester LE5 4PW, UK

Email: jmaybe@tiscali.co.uk

Received 22 July 2008; Accepted 5 August 2008

Published online 6 October 2008 in Wiley InterScience (www.interscience.wiley.com).

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website